Anika Therapeutics (ANIK) Receives News Impact Rating of 0.15

Media coverage about Anika Therapeutics (NASDAQ:ANIK) has been trending somewhat positive on Thursday, Accern reports. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anika Therapeutics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.185704966485 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern’s rankings:

A number of equities research analysts have issued reports on ANIK shares. Barrington Research increased their target price on shares of Anika Therapeutics from $53.00 to $57.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. BidaskClub lowered shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 14th.

Shares of Anika Therapeutics (NASDAQ ANIK) opened at $53.23 on Thursday. The stock has a market cap of $765.64, a P/E ratio of 24.99, a price-to-earnings-growth ratio of 2.74 and a beta of 1.46. Anika Therapeutics has a fifty-two week low of $41.64 and a fifty-two week high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.05. The company had revenue of $27.18 million for the quarter, compared to analyst estimates of $27.44 million. Anika Therapeutics had a net margin of 28.23% and a return on equity of 13.40%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.59 EPS. research analysts expect that Anika Therapeutics will post 1.9 EPS for the current year.

In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of the stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $54.48, for a total value of $286,020.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Charles H. Sherwood sold 22,228 shares of the stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $60.06, for a total transaction of $1,335,013.68. Following the completion of the sale, the chief executive officer now directly owns 158,297 shares in the company, valued at $9,507,317.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,886 shares of company stock worth $2,606,455. 6.57% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/28/anika-therapeutics-anik-receives-news-impact-rating-of-0-15.html.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

What are top analysts saying about Anika Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit